Note: Biopta (Glasgow, UK and Maryland, USA) is now REPROCELL’s Center for predictive Drug Discovery.
Note: Reinnervate (Durham, UK) is now part of REPROCELL’s Center for predictive Drug Discovery.
On the REPROCELL blog
Latest
Why mRNA Reprogramming Is the Key to Safer and Faster iPSC Generation?
Discover how mRNA reprogramming enhances the safety, efficiency, and scalability of iPSC generation for therapeutic applications. Explore REPROCELL's innovative technologies and services.
10 June 2025
New Therapeutic Targets: The Role of IL17-Related Genes in Precision Medicine
Discover how IL-17 related genes could revolutionize psoriasis treatment, offering new therapeutic targets and paving the way for precision medicine advancements.
09 June 2025
Balancing Efficacy and Cognitive Health In Bladder Assays
New approaches in OAB treatment focus on balancing efficacy and cognitive health, using alternatives to anticholinergics and personalized medicine to improve patient outcomes.
23 May 2025
Breaking Barriers in Women’s Health: The World’s First Live Birth Using Fertilo
Discover how Gameto achieved the world’s first live birth using Fertilo, a revolutionary in vitro oocyte maturation technology. Learn about its stem cell-driven innovation and how it's transforming fertility care for women worldwide.
21 May 2025
Key Strategies Central Labs Use to Fast-Track Time to Market
Learn how central labs use automation, outsourcing, and AI to accelerate drug development, reduce costs, and improve clinical trial accuracy and efficiency.
21 May 2025
.jpg?width=800&height=450&name=Biopta%20(Scottish%20Life%20Sciences).jpg)
